LiveWire Ergogenics (LVVV) AI Stock Analysis

LiveWire Ergogenics

(Other OTC:LVVV)

Select Model

Rating:27Underperform

Price Target:$0.01▲(1025.00% Upside)

Action:downgraded

Date:03/22/26

Dominated by poor financial performance (collapsing revenue, negative equity, cash burn) with no offsetting technical or valuation positives; high risk of insolvency.

Positive Factors

Cannabis-focused holding modelThe holding-company model centered on acquiring, developing and operating cannabis cultivation properties provides asset-backed optionality. Owning and operating properties can create diversified revenue levers (leases, operations, JV arrangements) and preserves strategic flexibility over months.

Negative Factors

Severe revenue collapse and volatilityA dramatic fall in sales to roughly $7.8K in 2025 from prior years shows extreme demand or execution deterioration. Such severe revenue volatility undermines predictable cash generation, complicates planning, and materially raises the risk that operations cannot sustainably cover costs or service obligations in the near term.

LiveWire Ergogenics (LVVV) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap: $380.80K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.4
Beta (1Y): 176.20
Revenue Growth: -38.48%
EPS Growth: 83.33%
Country: US
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

LiveWire Ergogenics Business Overview & Revenue Model

Company Description

LiveWire Ergogenics, Inc. (LVVV) focuses on developing and overseeing specialized real estate holdings, which it then licenses for the cultivation and production of artisanal, organically grown cannabis items. These premium products are intended for...

How the Company Makes Money

null

LiveWire Ergogenics Financial Statement Overview

Summary

Average of Income Statement (12), Balance Sheet (25), and Cash Flow (18) scores reflects severe revenue collapse, negative equity, cash burn, and operational distress despite prior high margins.

Income Statement

12Very Negative

Balance Sheet

25Negative

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	60.03K	7,835	304.12K	1.63M	1.94M	851.20K
Gross Profit	29.31K	-17.44K	285.16K	1.59M	1.80M	701.55K
EBITDA	-53.73K	-157.16K	322.18K	1.22M	1.07M	-2.68M
Net Income	-931.68K	-4.78M	78.72K	921.58K	684.12K	-3.43M
Balance Sheet
Total Assets	2.24M	2.26M	7.96M	7.74M	6.27M	4.52M
Cash, Cash Equivalents and Short-Term Investments	7,813	1,479	11.27K	27.87K	76.38K	199.95K
Total Debt	3.78M	3.05M	3.35M	3.34M	3.20M	2.85M
Total Liabilities	4.46M	3.78M	4.70M	4.62M	4.24M	3.61M
Stockholders Equity	-2.23M	-1.51M	3.24M	3.11M	2.03M	912.13K
Cash Flow
Free Cash Flow	9,200	-7,310	124.74K	682.37K	396.37K	-467.21K
Operating Cash Flow	9,204	-7,309	124.74K	682.37K	396.37K	-399.89K
Investing Cash Flow	0	0	-187.34K	-857.40K	-1.20M	-930.51K
Financing Cash Flow	0	0	46.00K	126.51K	684.50K	1.42M

LiveWire Ergogenics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

LVVV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	42Neutral	$3.84M	-0.18	-166.67%	―	―	88.77%
PRFX	38Underperform	$2.22M	-0.07	-72.87%	―	―	―
LVVV	27Underperform	$380.80K	-0.40	52.47%	―	-38.48%	83.33%
MSPR	19Underperform	$14	0.00	80.67%	―	―	―

* Healthcare Sector Average

Performance Comparison

LVVV and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
LVVV	LiveWire Ergogenics	―	―	―
PRFX	Painreform Ltd.	0.73	-5.07	-87.41%
MSPR	Msp Recovery, Inc.	0.01	-0.51	-98.08%
DRMA	Dermata Therapeutics, Inc.	0.78	-2.65	-77.34%
CERO	Cero Therapeutics Holdings, Inc.	0.01	-0.11	-91.74%
AKAN	Akanda Corp	1.04	-34.29	-97.06%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Mar 22, 2026

LiveWire Ergogenics AI Stock Analysis